Omega Fund Management, LLC
- SEC CIK
- 0001637359
- Latest filing
- Aug 14, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 11
- 0 vs. Q1 2024
- Portfolio value
- $135.0M
- −$20.0M (−12.9%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NUVBNuvation Bio Inc. | COM CL A | 13,275,884 | $38.8M | 28.7% | −796,456−5.7% | Reduced | History |
| LXEOLexeo Therapeutics, Inc. | COM | 2,355,904 | $37.8M | 28.0% | 00.0% | Unchanged | History |
| REPLReplimune Group, Inc. | COM | 2,461,319 | $22.2M | 16.4% | −540,000−18.0% | Reduced | History |
| ENGNenGene Therapeutics Inc. | COM | 1,076,357 | $10.2M | 7.5% | 00.0% | Unchanged | History |
| ALMSAlumis Inc. | COM | 653,225 | $8.69M | 6.4% | +653,225 | New | History |
| MORFMorphic Holding, Inc. | COM | 159,846 | $5.45M | 4.0% | 00.0% | Unchanged | History |
| SANASana Biotechnology, Inc. | COM | 843,750 | $4.61M | 3.4% | 00.0% | Unchanged | History |
| IMAImageneBio, Inc. | COM | 2,249,123 | $3.71M | 2.7% | 00.0% | Unchanged | History |
| IMUXImmunic, Inc. | COM | 1,788,160 | $1.98M | 1.5% | 00.0% | Unchanged | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 251,270 | $1.30M | 1.0% | 00.0% | Unchanged | History |
| ENGNWenGene Therapeutics Inc. | *W EXP 10/31/202 | 321,502 | $382.6K | 0.3% | −39,401−10.9% | Reduced | History |
Sold out since Q1 2024 (1)
Positions held at the end of Q1 2024 that are gone from this filing.